Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation

Chest

Volumn 150, Issue 6, 2016, Pages 1302-1312

  Noseworthy, Peter A ^a   Yao, Xiaoxi ^a   Abraham, Neena S ^a,b,c   Sangaralingham, Lindsey R ^a   McBane, Robert D ^a   Shah, Nilay D ^a,c,d  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c Optum Labs ^*  (United States)

^d OPTUM   (United States)

Author keywords

atrial fibrillation; bleeding; non vitamin K antagonist oral anticoagulants; stroke

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGED; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; CHEMICALLY INDUCED; COMPARATIVE STUDY; MIDDLE AGED; STROKE; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; CEREBRAL HEMORRHAGE; DABIGATRAN; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPENSITY SCORE; PYRAZOLES; PYRIDONES; RETROSPECTIVE STUDIES; RIVAROXABAN; STROKE; UNITED STATES;

EID: 85002798267     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.07.013     Document Type: Conference Paper

References (34)

1. 1 Wolf, P.A., Abbott, R.D., Kannel, W.B., Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:8 (1991), 983–988.
2. 2 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:13 (1994), 1449–1457.
3. 3 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:12 (2009), 1139–1151.
4. 4 Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:10 (2011), 883–891.
5. 5 Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:11 (2011), 981–992.
6. 6 Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:22 (2013), 2093–2104.
7. 7 Camm, A.J., Lip, G.Y., De Caterina, R., et al., ESC Committee for Practice Guidelines. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33 (2012), 2719–2747.
8. 8 Patel, P.A., Zhao, X., Fonarow, G.C., et al. Novel oral anticoagulant use among patients with atrial fibrillation hospitalized with ischemic stroke or transient ischemic attack. Circ Cardiovasc Qual Outcomes 8:4 (2015), 383–392.
9. 9 Olesen, J.B., Sorensen, R., Hansen, M.L., et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace 17:2 (2015), 187–193.
10. 10 Baker, W.L., Phung, O.J., Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes 5:5 (2012), 711–719.
11. 11 Rasmussen LH, Larsen TB, Graungaard T, Skjøth F, Lip GY. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis [published online ahead of print November 5, 2012]. BMJ. http://dx.doi.org/10.1136/bmj.e7097.
12. 12 Schneeweiss, S., Gagne, J.J., Patrick, A.R., Choudhry, N.K., Avorn, J., Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 5:4 (2012), 480–486.
13. 13 Lip, G.Y., Larsen, T.B., Skjøth, F., Rasmussen, L.H., Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 60:8 (2012), 738–746.
14. 14 Abraham, N.S., Singh, S., Alexander, G.C., et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ, 350, 2015, h1857.
15. 15 Go, A.S., Hylek, E.M., Phillips, K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:18 (2001), 2370–2375.
16. 16 Miyasaka, Y., Barnes, M.E., Gersh, B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114:2 (2006), 119–125.
17. 17 Freeman, J.V., Simon, D.N., Go, A.S., et al. Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes 8:4 (2015), 393–402.
18. 18 January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:21 (2014), e1–e76.
19. 19 Wallace, P.J., Shah, N.D., Dennen, T., Bleicher, P.A., Crown, W.H., Optum Labs: building a novel node in the learning health care system. Health Affairs 33:7 (2014), 1187–1194.
20. 20 Optum. Research data assets. https://www.optum.com/content/dam/optum/resources/productSheets/5302_Data_Assets_Chart_Sheet_ISPOR.pdf. Accessed June 22, 2015.
21. 21 Deyo, R.A., Cherkin, D.C., Ciol, M.A., Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:6 (1992), 613–619.
22. 22 Lip, G.Y.H., Nieuwlaat, R., Pisters, R., Lane, D.A., Crijns, H.J.G.M., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 137:2 (2010), 263–272.
23. 23 Pisters, R., Lane, D.A., Nieuwlaat, R., de Vos, C.B., Crijns, H.J., Lip, G.Y., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest Journal 138:5 (2010), 1093–1100.
24. 24 Hershman, D.L., Tsui, J., Wright, J.D., Coromilas, E.J., Tsai, W.Y., Neugut, A.I., Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. J Clin Oncol 33:9 (2015), 1053–1059.
25. 25 Lavallée, P.C., Meseguer, E., Abboud, H., et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol 6:11 (2007), 953–960.
26. 26 Austin, P.C., Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28 (2009), 3083–3107.
27. 27 Gayat, E., Resche-Rigon, M., Mary, J.Y., Porcher, R., Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study. Pharm Stat 11:3 (2012), 222–229.
28. 28 Grambsch, P.M., Therneau, T.M., Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:3 (1994), 515–526.
29. 29 Osterberg, L., Blaschke, T., Adherence to medication. N Engl J Med 353:5 (2005), 487–497.
30. 30 Tirschwell, D.L., Longstreth, W., Validating administrative data in stroke research. Stroke 33:10 (2002), 2465–2470.
31. 31 Gialdini, G., Nearing, K., Bhave, P.D., et al. Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA 312:6 (2014), 616–622.
32. 32 Noseworthy, P.A., Kapa, S., Deshmukh, A.J., et al. Risk of stroke after catheter ablation versus cardioversion for atrial fibrillation: a propensity-matched study of 24,244 patients. Heart Rhythm 12:6 (2015), 1154–1161.
33. 33 Roldan, V., Marin, F., Manzano-Fernandez, S., et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 62:23 (2013), 2199–2204.
34. 34 Cullen, M.W., Kim, S., Piccini, J.P. Sr., et al. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes 6:4 (2013), 461–469.